{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:54:46Z","timestamp":1790805286682,"version":"4.1.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Exogenous delivery of messenger RNA (mRNA) is emerging as a new class of medicine with broad applicability including the potential to treat rare monogenic disorders. Recent advances in mRNA technology, including modifications to the mRNA itself along with improvements to the delivery vehicle, have transformed the utility of mRNA as a potential therapy to restore or replace different types of therapeutic proteins. Preclinical proof-of-concept has been demonstrated for mRNA therapy for three different rare metabolic disorders: methylmalonic acidemia, acute intermittent porphyria, and Fabry disease. Herein, we review those preclinical efficacy and safety studies in multiple animal models. For all three disorders, mRNA therapy restored functional protein to therapeutically relevant levels in target organs, led to sustained and reproducible pharmacology following each dose administration of mRNA, and was well tolerated as supported by liver function tests evaluated in animal models including nonhuman primates. These data provide compelling support for the clinical development of mRNA therapy as a treatment for various rare metabolic disorders.<\/jats:p>","DOI":"10.1089\/hum.2019.090","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T07:22:44Z","timestamp":1560151364000},"page":"1180-1189","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["A New Era for Rare Genetic Diseases: Messenger RNA Therapy"],"prefix":"10.1177","volume":"30","author":[{"given":"Paolo G.V.","family":"Martini","sequence":"first","affiliation":[{"name":"Rare Diseases, Moderna, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin T.","family":"Guey","sequence":"additional","affiliation":[{"name":"Rare Diseases, Moderna, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.132"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat9143"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08852-4"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4278"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318269"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.46"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1619653114"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.7.4552"},{"key":"e_1_3_3_10_2","first-page":"9578","article-title":"Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential","volume":"44","author":"Strenkowska M","year":"2016","unstructured":"Strenkowska M, , Grzela R, , Majewski M, et al. Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential. Nucleic Acids Res, 2016; 44:9578\u20139590.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1261\/rna.065102.117"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx135"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.002"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.85"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.7b02664"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.03.010"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.049"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0199-z"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2019.02.003"},{"key":"e_1_3_3_21_2","first-page":"1993","volume-title":"GeneReviews(\u00ae)","author":"Manoli I","year":"1993","unstructured":"Manoli I, , Sloan JL, , Venditti CP. Isolated methylmalonic acidemia. In: Adam MP, , Ardinger HH, , Pagon RA, et al., eds. GeneReviews(\u00ae). Seattle, WA: University of Washington, Seattle, 1993:1993\u20132019."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1063-z"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000422"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e3180a0325f"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9621-3"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0130-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01986.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.01.051"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12804"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25304"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9544-4"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016080918"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0178-z"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.10.001"},{"key":"e_1_3_3_35_2","first-page":"57","article-title":"Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms","volume":"22","author":"Marsden JT","year":"2015","unstructured":"Marsden JT, , Guppy S, , Stein P, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep, 2015; 22:57\u201365.","journal-title":"JIMD Rep"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.10.026"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608634"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.01035.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03904.x"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807838"},{"key":"e_1_3_3_41_2","unstructured":"Alnylam. https:\/\/www.businesswire.com\/news\/home\/20150915005532\/en\/Alnylam-Reports-Positive-Initial-Clinical-Results-ALN-AS1 (last accessed March4 2019)."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.012"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.21.2771"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.11.008"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781118514672.ch7"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-011-0710-9"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/282487"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02567.x"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2019.090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:54:42Z","timestamp":1777449282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2019.090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1089\/hum.2019.090"],"URL":"https:\/\/doi.org\/10.1089\/hum.2019.090","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]}}}